Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics has entered into a distribution partnership with Interlux Group to expand the availability of its FebriDx® point-of-care diagnostic test in the Baltic region, covering Lithuania, Estonia, and Latvia. This collaboration strengthens Lumos’ presence in Europe, aligning with its strategy to broaden the reach of FebriDx® through established regional partners and enabling quicker adoption in primary care and other healthcare settings.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, point-of-care diagnostic testing technologies and offers both customized assay development and proprietary tests targeting infectious and inflammatory diseases. The company aims to enhance healthcare decisions through innovative diagnostic solutions.
Average Trading Volume: 4,667,047
Technical Sentiment Signal: Buy
Current Market Cap: A$185M
See more insights into LDX stock on TipRanks’ Stock Analysis page.